NTLA Q1 2018 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+20.2% YoY

Gross Profit

-$15M-201.2% margin

Operating Income

-$22M-300.3% margin

Net Income

-$21M-285.9% margin

EPS (Diluted)

$-0.51

QoQ Revenue Growth

+12.0%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$20M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$360M

Total Liabilities

$64M

Stockholders' Equity

$295M

Cash & Equivalents

$328M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$6M	+20.2%
Gross Profit	-$15M	-$7M	-108.2%
Operating Income	-$22M	-$13M	-73.2%
Net Income	-$21M	-$13M	-69.1%